Harrow, Inc.
HROW
Jodie situation report
Harrow, Inc.'s move is being confirmed by its market group.
HROW accounts for 14.0% of the group's measured movement across 5.2 effective names. raw member direction is mixed; 4 of 7 session-normalized paths align to the upside. Capital-flow agreement is 6%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
HROW was the first measured mover. HROW crossed its material path threshold at 15:40 ET. AVBP, ORKA, SYRE followed.
7 of 8 members in Clinical Biotechnology are active. 0 of 4 disclosed connections are confirming.
- At least 6 of 8 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as MLTX begins moving with the group.
Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.
Who this business touches
The relationships behind HROW
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
HROW is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.